An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.
Фаза 1 – тестване на безопасността при малка група хора
Заболявания:
Non-Hodgkin Lymphoma
Спонсор: F. Hoffmann-La Roche AG
Налично на:
БГ
Обобщение
Trial status: Authorised
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 52 participants
БГ
EN